Evidence map›Paper›PMID 38067583›Full record

ArticleMolecules (Basel, Switzerland)2023

Chemical Profiling, Quantitation, and Bioactivities of Ginseng Residue.

Shengyu Ge, Jinlong Liu, Yang Liu, Jiaqi Song, Hongfeng Wu, Lele Li, Heyun Zhu, Bo Feng

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Quality Evaluation ofFoods (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shengyu GeSchool of Pharmacy, Jilin Medical University, Jilin 132013, China.
Jinlong LiuSchool of Pharmacy, Jilin Medical University, Jilin 132013, China.
Yang LiuSchool of Pharmacy, Jilin Medical University, Jilin 132013, China.
Jiaqi SongSchool of Pharmacy, Jilin Medical University, Jilin 132013, China.
Hongfeng WuSchool of Pharmacy, Jilin Medical University, Jilin 132013, China.
Lele LiSchool of Pharmacy, Jilin Medical University, Jilin 132013, China.ORCID 0000-0002-2999-2344
Heyun ZhuSchool of Pharmacy, Jilin Medical University, Jilin 132013, China.
Bo FengSchool of Pharmacy, Jilin Medical University, Jilin 132013, China.
Jilin Medical University · CNYanbian University · CN

Funding

Natural Science Foundation Project from the Department of Science and Technology of Jilin Province 20210101238JCNatural Science Foundation Project from the Department of Science and Technology of Jilin Province YDZJ202201ZYTS268Science and Technology Project from the Department of Education of Jilin Province JJKH20230546KJ
6 · The paper itself

Abstract

Ginseng residue is a by-product stemming from the commercial extraction of ginsenosides. To assess the disparities between ginseng residue and ginseng tablet, we employed the ultra-high-performance liquid chromatography-quadrupole time-of-flight/mass spectrometry (UPLC-Q-TOF/MS) technique for sample analysis. The analyses revealed the presence of 39 compounds in both ginseng residue and ginseng tablets. Subsequently, the contents of total ginsenosides and total ginseng polysaccharides in the ginseng residue and ginseng tablet were determined. The results indicate that while only a small fraction of ginsenosides remained in the ginseng residue, a significant amount of polysaccharides was retained. Furthermore, our evaluation encompassed the antioxidant activities of both ginseng residue and ginseng tablets. Notably, ginseng residue exhibited robust antioxidant effects, thereby showcasing its potential for recycling as a functional food raw material.

Indexed as

GinsenosidesPanaxChromatography, High Pressure LiquidPolysaccharidesTabletsGinsenosidesPolysaccharidesTabletsantioxidant activityginseng polysaccharidesginseng residueginsenosidesUPLC-Q-TOF/MS

Identifiers

PMID38067583
PMCPMC10708035
OpenAlexW4389203126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.